Adding abciximab and reteplase does not reduce coronary deaths

摘要

Abciximab and reteplase combination therapy does not reduce mortality over one year,new data show. However, it represents a therapeutic advance with regard to non-fatal outcomes, researchers say. The data are part of a one-year follow-up of the global use of strategies to open coronary arteries (GUSTO V) trial which compared the efficacy of abciximab and a half-dose of reteplase (combination therapy) with full-dose reteplase in 16,588 patients with acute myocardial infaraction.